Mycophenolate mofetil treatment in patients with limited cutaneous systemic sclerosis is linked to a reduced need for escalation of vasoactive or vasodilator therapies for vascular complications.

Roche announced that the European Commission has approved Gazyva/Gazyvaro (obinutuzumab) in combination with mycophenolate mofetil (MMF) for the treatment of adult patients with active Class III or IV ...

Basel: Roche has announced that the European Commission has approved Gazyva/Gazyvaro (obinutuzumab) in combination with mycophenolate mofetil (MMF) for the treatment of adult patients with active ...

1 Nephrology Department, Cheikh Anta Diop University of Dakar, Dalal Jamm Hospital, Dakar, Senegal. 2 Nephrology Department, Cheikh Anta Diop University of Dakar, Aristide Le Dantec Hospital, Dakar, ...

To determine whether sirolimus (SIR) and cyclosporine (CSP) combined with post-transplantation cyclophosphamide (PTCy), after nonmyeloablative or reduced-intensity conditioning unrelated donor ...

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced that a post-hoc analysis of the 52-week, Phase 3 AURORA 1 ...

Children with frequently relapsing or steroid-dependent nephrotic syndrome had a significantly longer relapse-free survival period with tacrolimus than with mycophenolate mofetil. Relapse-free ...

CellCept (mycophenolate mofetil) is not safe to take while pregnant or breastfeeding. Certain factors, including the risks of fetal harm and pregnancy loss, may determine whether you should take the ...

Chronic graft-vs.-host disease (cGVHD) can be debilitating for people who have had an allogeneic stem cell transplant. In GVHD, the transplanted donor cells recognize the recipient’s tissues as ...